The invention provides an orodispersible solid pharmaceutical dosage unit having a weight between 30 and 1,000 mg, said dosage unit containing at least 100 g of an estetrol component selected from estetrol, estetrol esters and combinations thereof; wherein the solid dosage unit can be obtained by a process that comprises: providing a loading liquid comprising organic solvent; estetrol component and optionally one or more other pharmaceutically acceptable ingredients; mixing 1 part by weight of the loading liquid with 0.5-20 parts by weight of carrier particles to produce wet particles; removing organic solvent from the wet particles to produce loaded particles; optionally mixing the loaded particles with one or more tabletting excipients; and forming the loaded particles or the mixture of the loaded particles and the one or more tabletting excipients into a solid dosage unit. The solid dosage unit is easy to manufacture and perfectly suited for sublingual, buccal or sublabial administration.

A blue ink-jet ink that improves lightfastness of the same while maintaining its blue print color and a tablet including a part printed with the blue ink-jet ink. The blue ink-jet ink according to the present embodiment is an edible ink-jet that contains Brilliant Blue FCF (Blue No. 1 Colorant) and New Coccine (Red No. 102 Colorant) as colorants.

The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.

The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.

An inkjet ink in which a food color containing at least sodium copper chlorophyllin and a pigment other than sodium copper chlorophyllin is dispersed in a dispersion medium containing propylene glycol, and which prevents the occurrence of precipitation of the pigment components or other components even when the inkjet ink is stored for a long period of time, and there is also provided a tablet having a print pattern printed by the inkjet ink. The inkjet ink of the present embodiment, which is edible, comprises a food color containing at least sodium copper chlorophyllin and a pigment other than sodium copper chlorophyllin, and a dispersion medium containing propylene glycol, and has a propylene glycol content in the range of 0.001 mass % or more and 19 mass % or less relative to the total mass of the inkjet ink.

The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.

A drug dosage form is provided in the form of a solid tablet which is greater than 50% by weight the local anesthetic agent. The local anesthetic agent may be selected from the group consisting of an aminoamide, an aminoester, and a combination thereof. The drug tablet may be in the form of a mini-tablet which is greater than 70 wt % drug, with the balance being excipient. For example, the anesethetic agent may include lidocaine, in a salt or base form, combined with binder and lubricant excipients. Implantable drug delivery devices including the tablets are also provided, e.g., one or more of the drug tablets may be contained in a biocompatible housing. The drug tablets may be substantially cylindrical with flat end faces, and the device may have from 10 to 100 drug tablets aligned in the housing with the flat end faces of adjacent tablets abutting one another.

This invention relates to novel products of compressed Cannabis flower for medicinal and/or recreational use, and for methods of making such products.

An oral gastro-retentive delivery device is provided which unfolds rapidly upon contact with gastric juice. The device is configured in a collapsed configuration for oral intake and unfolding for gastric retention for a predetermined period of time and eventually reducing in size for passage through the rest of the GI track.

A composition for oral administration comprising a cannabinoid in combination with a stilbenoid or derivative thereof and a solubility enhancing agent is described. Oral dosage forms, in the form of dissolvable tablet or capsule with enhanced bioavailability and processes for preparing them are also disclosed. The processes include lyophilisation of the cannabinoid powder or cannabinoid-stilbenoid co-crystals to form a powder which is pressed into tablets. The powder may be generated from the co-crystals of the cannabinoid with pterostilbene or the powder may be formed by subsequently mixing the lyophilized cannabinoid with the stilbenoid before forming the tablet.